Identification

Name
Agomelatine
Accession Number
DB06594
Type
Small Molecule
Groups
Approved, Investigational
Description

Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis.

The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.

Structure
Thumb
Synonyms
  • Valdoxan
External IDs
S-20098 / S20098
International/Other Brands
Melitor (Servier Laboratories Ltd.) / Valdoxan (Servier Laboratories Ltd.)
Categories
UNII
137R1N49AD
CAS number
138112-76-2
Weight
Average: 243.301
Monoisotopic: 243.125928793
Chemical Formula
C15H17NO2
InChI Key
YJYPHIXNFHFHND-UHFFFAOYSA-N
InChI
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
IUPAC Name
N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
SMILES
COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1

Pharmacology

Indication

Agomelatine is indicated for the treatment of major depressive episodes in adults.

Structured Indications
Not Available
Pharmacodynamics

Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression

Mechanism of action

The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2C
antagonist
Human
AMelatonin receptor type 1A
agonist
Human
AMelatonin receptor type 1B
agonist
Human
Absorption

Bioavailability is less than 5%.

Volume of distribution
Not Available
Protein binding

> 95%

Metabolism

Hepatic (90% CYP1A2 and 10% CYP2C9).

Route of elimination
Not Available
Half life

<2 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Agomelatine.Experimental
AbirateroneThe serum concentration of Agomelatine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Agomelatine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Agomelatine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Agomelatine.Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Agomelatine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Agomelatine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Agomelatine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Agomelatine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Agomelatine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Agomelatine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Azaperone.Investigational, Vet Approved
AzelastineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe serum concentration of Agomelatine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Agomelatine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Agomelatine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Agomelatine is combined with Benzyl alcohol.Approved
BortezomibThe serum concentration of Agomelatine can be increased when it is combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Agomelatine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Agomelatine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Agomelatine.Approved, Investigational
BuprenorphineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Agomelatine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Agomelatine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Agomelatine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Agomelatine.Approved, Illicit, Vet Approved
CaffeineThe serum concentration of Agomelatine can be increased when it is combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Agomelatine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Agomelatine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Agomelatine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Agomelatine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Agomelatine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Agomelatine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Agomelatine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Agomelatine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Agomelatine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Agomelatine.Approved, Vet Approved
CitalopramThe serum concentration of Agomelatine can be increased when it is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Agomelatine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Agomelatine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Agomelatine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Agomelatine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Agomelatine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Agomelatine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Agomelatine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Agomelatine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Agomelatine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Agomelatine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Agomelatine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Agomelatine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Agomelatine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Agomelatine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Agomelatine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Agomelatine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Agomelatine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Agomelatine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Agomelatine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Agomelatine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Agomelatine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Agomelatine can be increased when it is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Agomelatine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Agomelatine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Agomelatine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Agomelatine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Agomelatine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Agomelatine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Agomelatine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Agomelatine.Approved
EthanolAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Agomelatine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Agomelatine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Agomelatine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Agomelatine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Agomelatine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Agomelatine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Agomelatine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Agomelatine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Agomelatine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Agomelatine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Agomelatine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Agomelatine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Agomelatine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Agomelatine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Agomelatine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Agomelatine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Agomelatine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Agomelatine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Agomelatine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Agomelatine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Agomelatine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Agomelatine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Agomelatine.Approved
HydrocodoneAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Agomelatine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Agomelatine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Agomelatine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Agomelatine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Agomelatine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Agomelatine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Agomelatine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Agomelatine.Approved
LidocaineThe serum concentration of Agomelatine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Agomelatine.Approved
LobeglitazoneThe serum concentration of Agomelatine can be increased when it is combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Agomelatine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Agomelatine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Agomelatine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Agomelatine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Agomelatine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Agomelatine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Agomelatine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Agomelatine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Agomelatine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Agomelatine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Agomelatine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Agomelatine.Approved
MethotrimeprazineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Agomelatine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Agomelatine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Agomelatine.Approved
MetyrosineAgomelatine may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Agomelatine can be increased when it is combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine.Approved, Illicit
MidostaurinThe serum concentration of Agomelatine can be increased when it is combined with Midostaurin.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Agomelatine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
MirtazapineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Agomelatine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Agomelatine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Agomelatine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nefazodone.Approved, Withdrawn
NevirapineThe serum concentration of Agomelatine can be increased when it is combined with Nevirapine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Agomelatine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Agomelatine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Agomelatine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Agomelatine.Approved
OpiumThe risk or severity of adverse effects can be increased when Agomelatine is combined with Opium.Approved, Illicit
OrphenadrineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Agomelatine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Agomelatine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Agomelatine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Agomelatine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Agomelatine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Agomelatine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Agomelatine.Approved
ParaldehydeAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Agomelatine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved
PerazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Agomelatine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Agomelatine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Agomelatine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Agomelatine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pomalidomide.Approved
PramipexoleAgomelatine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Agomelatine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Agomelatine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Agomelatine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Agomelatine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Agomelatine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Agomelatine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Agomelatine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Agomelatine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Agomelatine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Agomelatine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Agomelatine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Agomelatine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Agomelatine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Agomelatine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Agomelatine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Agomelatine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Romifidine.Vet Approved
RopiniroleAgomelatine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Agomelatine.Approved
RotigotineAgomelatine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Agomelatine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Agomelatine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Agomelatine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Agomelatine.Approved, Vet Approved
SimeprevirThe serum concentration of Agomelatine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Agomelatine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sultopride.Experimental
SuvorexantAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Agomelatine.Approved
Tenofovir disoproxilThe serum concentration of Agomelatine can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Agomelatine.Investigational
ThalidomideAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Agomelatine can be increased when it is combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Agomelatine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Agomelatine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Agomelatine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Agomelatine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiapride.Approved, Investigational
TiclopidineThe serum concentration of Agomelatine can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Agomelatine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Agomelatine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Agomelatine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Agomelatine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Agomelatine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Agomelatine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Agomelatine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Agomelatine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Agomelatine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Agomelatine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Agomelatine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zolazepam.Vet Approved
ZolpidemAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Agomelatine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe serum concentration of Agomelatine can be increased when it is combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Agomelatine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Jean-Claude Souvie, Isaac Gonzalez Blanco, Gilles Thominot, Genevieve Chapuis, Stephane Horvath, Gerard Damien, "Process for the synthesis and crystalline form of agomelatine." U.S. Patent US20050182276, issued August 18, 2005.

US20050182276
General References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999]
  2. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP: Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. doi: 10.1055/s-0031-1296459. [PubMed:18368944]
  3. Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14. [PubMed:17917564]
External Links
Human Metabolome Database
HMDB15636
KEGG Drug
D02578
PubChem Compound
82148
PubChem Substance
175427076
ChemSpider
74141
BindingDB
50035179
ChEBI
134990
ChEMBL
CHEMBL10878
PharmGKB
PA165958363
Wikipedia
Agomelatine
ATC Codes
N06AX22 — Agomelatine
MSDS
Download (15.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionMajor Depressive Disorder (MDD)1
3CompletedTreatmentMajor Depressive Disorder (MDD)6
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentSchizophrenia-spectrum-disorders / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableFibromyalgia / Major Depressive Disorder (MDD)1
Not AvailableRecruitingNot AvailableDepressive Disorders1
Not AvailableWithdrawnHealth Services ResearchMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSONot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00776 mg/mLALOGPS
logP2.83ALOGPS
logP2.04ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-0.94ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity71.64 m3·mol-1ChemAxon
Polarizability27.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9923
Caco-2 permeable+0.7464
P-glycoprotein substrateSubstrate0.5356
P-glycoprotein inhibitor INon-inhibitor0.6423
P-glycoprotein inhibitor IINon-inhibitor0.6412
Renal organic cation transporterNon-inhibitor0.5291
CYP450 2C9 substrateNon-substrate0.7647
CYP450 2D6 substrateSubstrate0.7219
CYP450 3A4 substrateSubstrate0.7276
CYP450 1A2 substrateInhibitor0.8543
CYP450 2C9 inhibitorNon-inhibitor0.7758
CYP450 2D6 inhibitorNon-inhibitor0.5445
CYP450 2C19 inhibitorNon-inhibitor0.7478
CYP450 3A4 inhibitorNon-inhibitor0.7746
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5467
Ames testAMES toxic0.6796
CarcinogenicityNon-carcinogens0.8958
BiodegradationNot ready biodegradable0.8296
Rat acute toxicity2.2095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9236
hERG inhibition (predictor II)Inhibitor0.6648
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-1910000000-17cebfbe6b9845617b5d

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-acetyl-2-arylethylamines. These are compounds containing an acetamide group that is N-linked to an arylethylamine.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
N-acetyl-2-arylethylamines
Alternative Parents
Naphthalenes / Anisoles / Alkyl aryl ethers / Secondary carboxylic acid amides / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
N-acetyl-2-arylethylamine / Naphthalene / Anisole / Alkyl aryl ether / Benzenoid / Secondary carboxylic acid amide / Ether / Organic oxide / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Organic cyclic compound binding
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1A
Uniprot ID
P48039
Uniprot Name
Melatonin receptor type 1A
Molecular Weight
39374.315 Da
References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Melatonin receptor activity
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1B
Uniprot ID
P49286
Uniprot Name
Melatonin receptor type 1B
Molecular Weight
40187.895 Da
References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Carney RM, Shelton RC: Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Oct;12(15):2411-9. doi: 10.1517/14656566.2011.607812. [PubMed:21916789]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Dolder CR, Nelson M, Snider M: Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008 Dec;42(12):1822-31. doi: 10.1345/aph.1L296. Epub 2008 Nov 25. [PubMed:19033480]

Drug created on March 19, 2008 10:39 / Updated on November 09, 2017 03:54